Publications

Conclusions:

• The impact of ARID1A mutations was analysed using 7978 colorectal cancer samples.
• ARID1A mutation was linked to immune activation, right-sided tumour and early stage.
• ARID1A mutation may be a biomarker for chemotherapy/radiotherapy and targeted therapy.